Inactivated SARS-CoV-2 vaccine (Vero cell) (Beijing Bio-Institute)

Coronavirus disease 2019 (COVID‐19) is a lethal global pandemic that originated in Wuhan, China at the end of 2019. As with other viral infectious diseases, the introduction of an effective vaccine is crucial for stopping the spread of the pandemic.In Iraq the COVID‐19 vaccination campaign started on March 2, 2021.

To determine the influence of the vaccine on new virus infection in Baghdad in terms of its effectiveness on the illness, hospitalization, and mortality.

A prospective observational study of patients with SARS‐CoV‐2 infection who were had a newly positive Real time PCR testing for SARS‐CoV‐2 at Al‐Yarmouk Hospital or Al‐Adel Primary Health Care Center, and correlate their symptoms to their state of vaccination.

A total of 539 patients tested positive for COVID‐19 via PCR (328 females and 211 males). Among these, 265 patients (49.2%) were vaccinated, while 274 (50.8%) were not. Being vaccinated and receiving the full doses showed the strongest association with decreased disease severity, reduced hospitalization rates, and lower mortality rates ( p  < 0.05 for all). The type of vaccination was significantly correlated with disease severity ( p  < 0.001), with more severe or critical symptoms reported in patients vaccinated with BBIBP‐CorV compared to those vaccinated with BNT162b2 or ChAdOx1 nCoV‐19 (AZD1222). However, no correlation was found with hospitalization or mortality rates.

COVID‐19 vaccination, while not preventing infection, markedly reduced disease severity and mortality—especially with full dosing and among high‐risk groups. The differential effectiveness observed among vaccine types highlights the importance of optimizing vaccine strategies based on real‐world outcomes, particularly in resource‐constrained settings like Iraq.

To develop immunity against Covid-19, vaccination was prioritized by World Health Organization (WHO). According to WHO, at least 70% of a population should be vaccinated to develop herd immunity. For this purpose, several kinds of vaccination had been introduced. One of them was Sinopharm inactivated Covid 19 vaccine, that was administered for a trial purpose to the medical students from 16th august 2021. So our purpose was to see the side effects following vaccination to sweep out the fear regarding Sinopharm vaccination. This cross-sectional analytical study was carried out from June to September 2021, among 228 medical students to find out the side effects after receiving 1st and 2nd dose of Covid-19 vaccines. Data were presented in both frequencies and percentages. Vaccine site pain was complained by 84.0% students after first dose and 78.0% students after 2nd dose. Many of the students complained of headache (49.8% after 1st dose, 38.8% after 2nd dose), fever (36.0% after 1st dose, 17.2% after 2nd dose). Some of students complained of muscle pain joint pain, which resolved within a short period. From this study; it was found that, adverse effect following 1st and 2nd dose of Sinopharm were mild, common and non-life threatening.